Niquitin Przezroczysty (Nicotine)

Nicotine, the active ingredient in Niquitin Przezroczysty, is a nicotinic receptor agonist presented as a transdermal patch for transdermal use. It is employed to reduce withdrawal symptoms and cravings associated with nicotine dependence, thereby supporting adults who wish to quit smoking and can be part of a comprehensive cessation program that includes counseling and behavioral support.

GNH USA supplies Niquitin Przezroczysty as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Niquitin Przezroczysty is a nicotine transdermal system used in smoking cessation therapy.

- Smoking cessation: helps adult smokers reduce cravings and withdrawal symptoms to achieve abstinence. - Nicotine dependence: alleviates physiological dependence on nicotine during the quitting process. - Relapse prevention: supports maintenance of abstinence after initial cessation.

Niquitin Przezroczysty may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Skin irritation at the application site - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Allergic reaction (rash, swelling, or hives) - Cardiovascular events such as chest pain or arrhythmia

Before using Niquitin Przezroczysty, consider the following precautions.

- Assess nicotine dependence level: evaluate the patient’s smoking history and readiness to quit. - Avoid use in patients with recent myocardial infarction: contraindicated in recent cardiac events. - Do not apply to damaged or irritated skin: ensure skin integrity before placement. - Rotate application sites: change location each day to minimize local irritation. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Niquitin Przezroczysty can interact with several medication classes.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): may increase risk of hypertensive crisis. - Certain antihypertensive drugs (e.g., beta‑blockers): nicotine can counteract blood pressure control. - CYP2A6 inhibitors: may raise systemic nicotine levels.

Moderate Interactions (Monitor Closely): - Caffeine: nicotine may enhance stimulant effects, leading to increased heart rate. - Alcohol: combined use may augment sedation or dizziness.